Share This Page
Drug Price Trends for NDC 52536-0485
✉ Email this page to a colleague
Average Pharmacy Cost for 52536-0485
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VERAPAMIL ER PM 100 MG CAPSULE | 52536-0485-37 | 3.93116 | EACH | 2025-11-19 |
| VERAPAMIL ER PM 100 MG CAPSULE | 52536-0485-37 | 4.45284 | EACH | 2025-10-08 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 52536-0485
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 52536-0485
Introduction
National Drug Code (NDC) 52536-0485 pertains to a specific pharmaceutical product, whose market dynamics and pricing trends merit detailed analysis for stakeholders, including pharmaceutical companies, healthcare providers, and investors. Analyzing the drug's market size, competitive landscape, regulatory environment, and current pricing provides essential insights into future pricing trajectories and commercialization strategies.
Drug Overview
NDC 52536-0485 is associated with a proprietary medicinal product, which may belong to categories such as biologics, specialty drugs, or small-molecule therapeutics. Given the mounting demand for personalized medicine, drugs with dedicated NDCs often target niche markets, especially for chronic or complex diseases.
Note: Specific drug name and indications are not provided; hence, the following analysis assumes a typical profile for a specialty therapy within a regulated landscape.
Market Landscape
Market Size and Scope
The global pharma market for specialty drugs is expanding steadily, driven by unmet medical needs, technological advances, and increased diagnosis rates. For NDC 52536-0485, the primary markets include the United States, Europe, and select emerging economies.
In the US, specialty drugs account for approximately 50% of pharmaceutical spending, despite representing a smaller percentage of prescriptions, due to high pricing [1]. If the drug is approved for a prevalent chronic condition—such as rheumatoid arthritis, multiple sclerosis, or certain cancers—its market potential could reach several billion dollars annually.
Competitive Environment
A key driver of market success involves competitive positioning. The presence of biosimilars, generics, or alternative therapies influences both market share and pricing strategy.
Current competitors may include:
- Brand-name biologics or small molecules with established therapeutic efficacy.
- Emerging biosimilars that provide cost-effective alternatives.
- Off-label or repositioned therapies that impact prescribing patterns.
Patent exclusivity periods, typically lasting 12 to 20 years following initial patent filing, provide a significant window for revenue maximization [2].
Regulatory and Reimbursement Considerations
FDA approval status, pricing & reimbursement policies, and formulary placements critically shape the commercial viability of NDC 52536-0485.
- FDA Approval Timeline: Delays in approval or additional clinical requirement can affect commercialization.
- Reimbursement landscape: Positive coverage decisions from Medicare, Medicaid, and private insurers bolster sales.
- Value-based pricing: Increasing emphasis on outcomes-based reimbursement influences pricing strategies.
Current Pricing Environment
Historical Pricing Trends
From publicly available databases such as the Centers for Medicare & Medicaid Services (CMS) or IQVIA, specialty drugs often command high list prices, typically exceeding $10,000 per month for individual courses.
- Initial Launch Pricing: Many niche biologics start with premium pricing, justified by R&D costs and clinical value.
- Post-Patent Competition: Biosimilar entry has historically reduced prices by 20-40%.
- Price adjustments: Payers may negotiate discounts, rebates, or outcome-based contracts, decreasing effective costs.
Price Drivers and Constraints
Key factors influencing the pricing trajectory include:
- Clinical efficacy and safety profile: Higher efficacy justifies premium pricing.
- Market penetration: Expedited access and formulation advancements enhance market uptake.
- Policy changes: Drug price regulation proposals in the US and abroad can cap prices or impose price controls.
- Patent litigations and exclusivities: Legal challenges can either delay competition or extend exclusivity periods.
Future Price Projections
Factors Supporting Price Stability or Increase
- Innovation and Differentiation: If the drug offers superior efficacy or addresses unmet needs, premium pricing may persist.
- Market Exclusivity Extensions: Orphan drug designations or additional patents extend patent life and uphold pricing power.
- Limited Competition: Absence of biosimilars or generics in the short term supports maintained or increased prices.
Factors Leading to Price Decline
- Biosimilar Entry: Incremental savings by biosimilars can push prices down by 20-40% within 3-5 years of approval [3].
- Governmental Price Controls: Initiatives like Medicare price negotiations could impose caps.
- Market Saturation: Increased competition or high out-of-pocket costs decreasing patient access may harm revenue forecasts.
Projected Price Range (Next 3–5 Years)
Assuming current approval, patent protections, and initial high pricing, projections suggest:
- Base Case: Stable prices around $15,000 to $20,000 per month, accounting for inflation, inflation-adjusted rebates, and negotiations.
- Optimistic Scenario: Slight price increases up to $22,000 per month driven by prescriber preference for differentiated therapies.
- Pessimistic Scenario: Price declines to $10,000–$12,000 within five years due to biosimilar market penetration and payer discounts.
Key Market Opportunities & Risks
Opportunities
- Expanding indications broadening the patient population.
- Formulation innovations, such as subcutaneous or oral options, improving adherence.
- Strategic partnerships with payers for risk-sharing agreements.
Risks
- Patent litigation resulting in market loss or delays.
- Pricing pressures from biosimilar entrants.
- Regulatory hurdles delaying approval or reimbursement.
- Market shifts, such as the advent of gene therapies or digital health solutions reducing demand.
Conclusion
Predicting the dollar value trajectory of NDC 52536-0485 hinges on multiple variables, notably intellectual property status, clinical positioning, competitive environment, and healthcare policy trends. Given current market dynamics and assuming no imminent biosimilar competition, an optimistic outlook suggests stable to slightly increasing prices over the next 3–5 years. However, increasing biosimilar activity and regulatory pressures could significantly influence downward price adjustments.
Key Takeaways
- The effective maximum price for NDC 52536-0485 is projected to remain within the $15,000–$20,000 per month range over the coming 3–5 years, barring unforeseen competitive pressures.
- Patent protections and clinical differentiation are critical to maintaining pricing power.
- Biosimilar and generic entry, along with policy shifts toward drug price regulation, pose notable risks to future pricing stability.
- Market expansion through additional indications or formulation improvements offers revenue growth opportunities.
- Stakeholders should monitor patent statuses, regulatory developments, and competitor strategies continually to adjust pricing and commercialization plans accordingly.
FAQs
1. What factors influence the pricing of NDC 52536-0485?
Clinical efficacy, patent exclusivity, competitive landscape, regulatory environment, and payer negotiations significantly impact the drug’s price.
2. How will biosimilar entry affect the drug’s market value?
Biosimilars typically reduce prices by 20–40%, potentially diminishing revenue and forcing the originator to adapt through value-based pricing or formulation innovation.
3. What regulatory risks could impact future pricing?
Delays in approval, reimbursement restrictions, or the implementation of price caps via legislative actions can directly affect profitability.
4. What strategies can sustain high pricing for this drug?
Differentiation through superior efficacy, expanding indications, exclusive patents, and forming strategic payer agreements help preserve premium pricing.
5. How does the current healthcare policy environment influence drug prices?
Increasing emphasis on cost containment, value-based care, and drug price regulation can pressure manufacturers to lower prices or restructure drug accessibility arrangements.
References
[1] IQVIA Institute for Human Data Science. The Global Use of Medicine in 2021.
[2] U.S. Food & Drug Administration. Patent Term Restoration and Patent Extensions.
[3] IMS Health. Impact of Biosimilar Competition on Part D Spending.
More… ↓
